Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health is advancing its FDA-approved drug crofelemer as a novel oral therapy for rare intestinal failure disorders, specifically microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The company highlighted proof-of-concept results showing a liquid formulation of crofelemer reduced the need for parenteral support (TPN/IV fluids) by up to 37% in MVID patients and up to 15% in SBS-IF patients.
Key figures
- Drug Name
- crofelemer
- Phase Of Trial
- pivotal
- Nda target date
- mid-2027
- Tpn reduction mvid
- up to 37%
- Tpn reduction sbs if
- up to 15%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.